Anzeige
Mehr »
Login
Mittwoch, 13.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Kolumbiens nächster Kupferriese? Warum Investoren dieses 14.000-Meter-Bohrprogramm beobachten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
347 Leser
Artikel bewerten:
(1)

Harrogate Group Plc - Interim Results; 1st April to 30th Sept 2020

Finanznachrichten News

Harrogate Group Plc - Interim Results; 1st April to 30th Sept 2020

PR Newswire

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY HARROGATE GROUP PLC TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS AMENDED ("MAR"). ON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE ("RIS"), THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

HARROGATE GROUP PLC
(formerly Iberian Gold plc; "Harrogate" or the "Company")

RESULTS FOR THE PERIOD ENDED 30THSEPTEMBER 2020

Chairman's Statement

The Directors present below the condensed, abridged, unaudited financial statements for the half-year ended 30thSeptember 2020, which show a loss before taxation of £(63,559) (30thSeptember 2019: £0)) and cash-at-bank of £1 (30thSeptember 2019: £1). The financial statements which follow have not been reviewed by the Company's statutory auditors. The loss for the half-year was in line with the Directors' expectations at the beginning of the period under review.

Trading Performance

During the period under review, the Company continued to be operationally dormant. We anticipate commencement of operations as soon as prevailing government restrictions permit.

Other Developments

Shortly prior to the beginning of the period under review, for the purposes of seeking admission to the Aquis Exchange Growth Market ("AQSE") ("Admission"), the Company appointed Keith, Bayley, Rogers & Co. Limited as AQSE Corporate Adviser. In September 2020, the Company issued 100,000,000 new ordinary vendor consideration shares to the shareholders of Greencore Commercial Limited ("Greencore"), a private company, in a related party transaction in which Greencore acquired the education and training assets of Ngage Training and the Company acquired 100 per cent. of Greencore's issued share capital. This transaction was approved by Harrogate's shareholders in general meeting.

Post- Balance Sheet Events

i. On 9thNovember 2020, the whole of the Company's issued ordinary share capital was admitted to AQSE.

ii. On the same day, the Company was pleased to confirm the appointment (which had been conditional upon Admission) of Sir Aubrey Brocklebank, Bt. as an independent, non-executive Director of the Company.

Reginald Brealey,

Chairman,

24thDecember 2020

Harrogate Group plc: Condensed Profit and Loss Account
for the period ended 30 September 2020

Notes
30-Sept
2020
30-Sept
2019
££
Operating expenses1, 4(63,559)-
Operating loss(63,559)-
Loss on ordinary activities before taxation(63,559)-
_ (63,559)
Total comprehensive loss for the period attributable to members3(63,559)Nil

Harrogate Group plc: Condensed Balance Sheet
as at 30 September 2020
Notes30-Sep
2020
30-Sep
2019
££
Fixed assets
Investment in subsidiary25,000,000-
5,000,000-
Current assets
Cash at bank and in hand11
11
Creditors: amounts falling due within one year(146,947)(83,388)
Net current liabilities(146,946)(83,387)
Net assets4,853,054(83,387)
Capital and reserves
Called up share capital12,785,3367,785,336
Share premium6,455,0186,455,018
Shares to be issued5,430,5575,430,557
Profit and loss account(19,817,857)(19,754,298)
Shareholders' funds4,853,054(83,387)

Harrogate Group plc: Condensed Statement of Changes in Equity
for the period ended 30 September 2020
Share
capital
Share
premium
Shares to be
issued
Profit
and loss
account
Total
£ £ £ £ £
At 1 April 20197,785,3366,455,0185,430,557(19,754,298)(83,387)
Loss for the financial period-----
At 30 September 20197,785,3366,455,0185,430,557(19,754,298)(83,387)
At 1 April 20207,785,3366,455,0185,430,557(19,754,298)(83,387)
Issue of ordinary shares5,000,000---5,000,000
Loss for the financial period---(63,559)(63,559)
At 30 September 202012,785,3366,455,0185,430,557(19,817,857)4,853,054

Harrogate Group plc: Condensed Cashflow Statement
as at 30 September 2020
30-Sept
2020
30-Sept
2019
££
Cashflows from operating activities
Operating loss(63,559)-
Movement in working capital:
(Decrease)/ increase in trade and other payables63,559Nil
-
Cash and cash equivalents at beginning of the period 1 1
Cash and cash equivalents at end of the period1
1
1
1

Notes* to the Condensed, Abridged Financial Statements

for the period 1stApril 2020 to 30thSeptember 2020:

1 Financial information

The financial information set out above does not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006. It has been prepared on a going concern basis in accordance with the recognition and measurement criteria of the IFRS as adopted by the European Union.

The accounting policies used in the preparation of this set of condensed interim financial statements are consistent with those which will be applied to the preparation of the Company's annual financial statements for the year ending 31stMarch 2021. Statutory accounts for a dormant company for the year ended 31stMarch 2020 were approved by the board of directors and delivered to the Registrar of Companies on 9thApril 2020. The accounts were unaudited.

The financial information for the period ended 30thSeptember 2020 has not been audited or reviewed. As permitted, the Company has chosen not to adopt IAS34 'Interim Financial Statements' in preparing this financial information.

2 Fixed assets: Investment in subsidiary

On 21stSeptember 2020, the Company acquired Greencore Commercial Limited which principally consists of a long-established youth training scheme. The assets were independently valued at £5,000,000. The consideration for the transaction was the issuance of 100,000,000 ordinary shares of 5p each at par.

3 Earnings per share

The calculation of basic earnings per share is based on the loss attributable to ordinary shareholders divided by the weighted average of ordinary shares in issue being 78,125,383 during the period. This results in a loss per share of 0.00p (2019 - 0.00p).

4 Directors' remuneration

The Directors received no remuneration during the period.

* Note 1 applies to the condensed, abridged financial statements above, as a whole.

The Directors of Harrogate Group, after due and careful enquiry, accept responsibility for the contents of this announcement.

REGULATORY ANNOUNCEMENT ENDS.

Enquiries:

Keith, Bayley, Rogers & Co. Limited
Graham Atthill-Beck: +44 20 7464 4091/ +44 7506 43 41 07 / Graham.Atthill-Beck@kbrl.co.uk
Brinsley Holman: +44 20 7464 4098 / Brinsley.Holman@kbrl.co.uk

Harrogate Group Public Limited Company
Michael Burton: +44 7894 23 36 94/ enquiries@harrogategroupplc.co.uk

© 2021 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.